| MeSH term | MeSH ID | Detail |
|---|---|---|
| Infection | D007239 | 6 associated lipids |
| Abnormalities, Multiple | D000015 | 13 associated lipids |
| Hypersensitivity, Delayed | D006968 | 43 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Bone Diseases | D001847 | 4 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Ulcer | D014456 | 16 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Obesity | D009765 | 29 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
| Bradycardia | D001919 | 13 associated lipids |
| Hemorrhage | D006470 | 15 associated lipids |
| Proteinuria | D011507 | 30 associated lipids |
| Lymphoma | D008223 | 18 associated lipids |
| Femur Head Necrosis | D005271 | 5 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Drug Hypersensitivity | D004342 | 20 associated lipids |
| Eye Diseases | D005128 | 12 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morrissey PE | Prope tolerance: is it the end or the means? | 2009 | Transplantation | pmid:19502973 |
| Egawa H et al. | FK506 conversion therapy in pediatric liver transplantation. | 1994 | Transplantation | pmid:7513911 |
| Moss MC et al. | Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? | 2014 | Transplantation | pmid:24492429 |
| Yang CW et al. | Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. | 2001 | Transplantation | pmid:11740384 |
| Narayanan M et al. | Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. | 2013 | Transplantation | pmid:23423268 |
| Firdaous I et al. | Pediatric intravenous FK506--how much are we really infusing? | 1994 | Transplantation | pmid:7517079 |
| Donnadieu B et al. | Central retinal vein occlusion-associated tacrolimus after liver transplantation. | 2014 | Transplantation | pmid:25955343 |
| Soccal PM et al. | Improvement of drug-induced chronic renal failure in lung transplantation. | 1999 | Transplantation | pmid:10428288 |
| Lee CM et al. | Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. | 1997 | Transplantation | pmid:9371670 |
| Dhar DK et al. | Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. | 1993 | Transplantation | pmid:7506456 |
| Yates CJ et al. | Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. | 2013 | Transplantation | pmid:23902993 |
| Sharif A et al. | Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. | 2010 | Transplantation | pmid:20145524 |
| Moutabarrik A et al. | FK506-induced kidney tubular cell injury. | 1992 | Transplantation | pmid:1281562 |
| Uemura T et al. | Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. | 2011 | Transplantation | pmid:21841541 |
| Ho ET et al. | Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. | 2013 | Transplantation | pmid:23542469 |
| Aw MM et al. | Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. | 2001 | Transplantation | pmid:11544444 |
| Fujii Y et al. | Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. | 1989 | Transplantation | pmid:2472025 |
| Terakura M et al. | Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. | 1998 | Transplantation | pmid:9721804 |
| Veroux M et al. | Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. | 2012 | Transplantation | pmid:22298033 |
| Kai N et al. | Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. | 1993 | Transplantation | pmid:7682740 |
| Jacobson PA et al. | Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. | 2011 | Transplantation | pmid:21206424 |
| Nolan TJ and Schad GA | Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. | 1996 | Transplantation | pmid:8878405 |
| Klupp J et al. | Indications of mycophenolate mofetil in liver transplantation. | 2005 | Transplantation | pmid:16286893 |
| Opelz G and Döhler B | Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. | 2009 | Transplantation | pmid:19300179 |
| Rostambeigi N et al. | Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. | 2011 | Transplantation | pmid:21200364 |
| Jordan ML et al. | Tacrolimus rescue therapy for renal allograft rejection--five-year experience. | 1997 | Transplantation | pmid:9020321 |
| Reich DJ et al. | Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. | 2005 | Transplantation | pmid:16003228 |
| Hardinger KL et al. | A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. | 2005 | Transplantation | pmid:16003231 |
| Ericzon BG et al. | FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. | 1992 | Transplantation | pmid:1384189 |
| Pascual J et al. | Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. | 2004 | Transplantation | pmid:15599321 |
| Peng Y et al. | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. | 2013 | Transplantation | pmid:23263506 |
| Stephen M et al. | Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. | 1989 | Transplantation | pmid:2463701 |
| Nakazawa Y et al. | Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. | 1998 | Transplantation | pmid:9808496 |
| Meiser BM et al. | Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? | 2004 | Transplantation | pmid:15446320 |
| Griffith BP et al. | A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. | 1994 | Transplantation | pmid:7512292 |
| Jordan ML et al. | FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. | 1994 | Transplantation | pmid:7512293 |
| Sun S et al. | Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. | 1996 | Transplantation | pmid:8633368 |
| Kashu Y et al. | The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. | 1996 | Transplantation | pmid:8633382 |
| VÃtko S et al. | Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. | 2005 | Transplantation | pmid:16378069 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |